Article by Colette Gallagher, Public Affairs
Mayo Clinic researchers reported in the Journal of the National Cancer Institute the results of the Breast Cancer Genome-Guided Therapy (BEAUTY) study designed to help researchers and physicians better understand why current standard chemotherapy stops breast cancer in some women but fails in others.
Tumor sequencing is increasingly used to select treatment for patients with cancer, but its role in women with newly diagnosed breast cancer is unknown. Mayo Clinic researchers looked at the feasibility of obtaining cancer tumor genome sequencing data and creating patient-derived mouse avatars in the chemotherapy before surgery setting.
This data provides an invaluable tool for drug development and targeted therapy, especially in chemotherapy resistant tumors.
“There is great interest to use tumor sequencing data to guide therapy,” says Matthew Goetz, M.D., medical oncologist and co-chair of the BEAUTY study. “However, there are limited data as to whether this approach is useful in women with newly diagnosed breast cancer who are recommended chemotherapy prior to breast surgery,” he added.
Tags: #Breast Cancer Genome-Guided Therapy study, #DNA sequencing tests, #Journal of the National Cancer Institute, #tumor sequencing, breast cancer, center for individualized medicine, chemotherapy, Dr. Judy Boughey, Dr. Matthew Goetz, mayo clinic, Mayo Clinic Cancer Center, medical research, Precision Medicine